Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.
The overlapping epidemiology of human immunodeficiency virus (HIV) infection and tuberculosis (TB) and the catastrophic consequences of the interactions between the two epidemics have led to increased morbidity and mortality due to HIV-associated TB. While effective therapy is available for both conditions, there are major challenges in the concurrent treatment of HIV and TB co-infection. This review examines the interactions between HIV and TB infections and reviews the current status of highly active antiretroviral therapy (HAART) in patients with co-infection. Specific questions relating to optimal timing of concurrent HAART, challenges to concurrent HAART, optimal regimens and future considerations are discussed.
Kwara
A
A
Division of Infectious Diseases, Department of Medicine, Miriam Hospital/Brown Medical School, Providence, Rhode Island 02926, USA. akwara@lifespan.org
Flanigan
T P
TP
Carter
E J
EJ
D000328:Adult; D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods* / Q000639:trends; D000995:Antitubercular Agents / Q000627:therapeutic use; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy*
D044966:Anti-Retroviral Agents; D000995:Antitubercular Agents